Free Trial
NASDAQ:OPT

Opthea (OPT) Stock Price, News & Analysis

Opthea logo
$3.41 0.00 (0.00%)
As of 03/28/2025

About Opthea Stock (NASDAQ:OPT)

Key Stats

Today's Range
$3.41
$3.41
50-Day Range
$3.07
$5.92
52-Week Range
$1.79
$6.30
Volume
N/A
Average Volume
26,061 shs
Market Capitalization
$524.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$1.33
Consensus Rating
Hold

Company Overview

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Remove Ads

Opthea Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
14th Percentile Overall Score

OPT MarketRank™: 

Opthea scored higher than 14% of companies evaluated by MarketBeat, and ranked 902nd out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Opthea has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    Opthea has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Opthea's stock forecast and price target.
  • Earnings Growth

    Earnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share.

  • Percentage of Shares Shorted

    0.35% of the float of Opthea has been sold short.
  • Short Interest Ratio / Days to Cover

    Opthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Opthea does not currently pay a dividend.

  • Dividend Growth

    Opthea does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.35% of the float of Opthea has been sold short.
  • Short Interest Ratio / Days to Cover

    Opthea has a short interest ratio ("days to cover") of 16.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Opthea has recently increased by 20.66%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Opthea has a news sentiment score of -0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 43 news articles for Opthea this week, compared to 3 articles on an average week.
  • MarketBeat Follows

    4 people have added Opthea to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Opthea insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.20% of the stock of Opthea is held by insiders.

  • Percentage Held by Institutions

    55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Opthea's insider trading history.
Receive OPT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Opthea and its competitors with MarketBeat's FREE daily newsletter.

OPT Stock News Headlines

FY2025 EPS Estimates for Opthea Reduced by Leerink Partnrs
New “Trump” currency proposed in DC
According to one of the most connected men in Washington… A surprising new bill was just introduced in Washington. Its purpose: to put Donald Trump’s face on the $100 note. All to celebrate a new “golden age” for America.
What is HC Wainwright's Forecast for Opthea FY2025 Earnings?
Opthea (NASDAQ:OPT) Downgraded to Hold Rating by Leerink Partnrs
See More Headlines

OPT Stock Analysis - Frequently Asked Questions

Opthea's stock was trading at $3.93 at the beginning of 2025. Since then, OPT shares have decreased by 13.2% and is now trading at $3.41.
View the best growth stocks for 2025 here
.

Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at a price of $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

Opthea's top institutional shareholders include Hsbc Holdings PLC (0.10%), Millennium Management LLC (0.04%), Citadel Advisors LLC (0.01%) and OLD Mission Capital LLC (0.01%).

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST) and Zendesk (ZEN).

Company Calendar

Today
3/29/2025
Fiscal Year End
6/30/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OPT
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$1.33
High Stock Price Target
$2.00
Low Stock Price Target
$1.00
Potential Upside/Downside
-60.9%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$87,666.00
Price / Cash Flow
N/A
Book Value
($0.56) per share
Price / Book
-6.09

Miscellaneous

Free Float
148,981,000
Market Cap
$524.84 million
Optionable
Not Optionable
Beta
1.12
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:OPT) was last updated on 3/30/2025 by MarketBeat.com Staff
From Our Partners